Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

368 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance.
Amodio V, Lamba S, Chilà R, Cattaneo CM, Mussolin B, Corti G, Rospo G, Berrino E, Tripodo C, Pisati F, Bartolini A, Aquilano MC, Marsoni S, Mauri G, Marchiò C, Abrignani S, Di Nicolantonio F, Germano G, Bardelli A. Amodio V, et al. Among authors: bardelli a. Cancer Cell. 2023 Jan 9;41(1):196-209.e5. doi: 10.1016/j.ccell.2022.12.003. Epub 2022 Dec 29. Cancer Cell. 2023. PMID: 36584674 Free PMC article.
Case report: Preclinical efficacy of NEDD8 and proteasome inhibitors in patient-derived models of signet ring high-grade mucinous colorectal cancer from a Lynch syndrome patient.
Torchiaro E, Petti C, Arena S, Sassi F, Migliardi G, Mellano A, Porporato R, Basiricò M, Gammaitoni L, Berrino E, Montone M, Corti G, Crisafulli G, Marchiò C, Bardelli A, Medico E. Torchiaro E, et al. Among authors: bardelli a. Front Oncol. 2023 Feb 2;13:1130852. doi: 10.3389/fonc.2023.1130852. eCollection 2023. Front Oncol. 2023. PMID: 36816936 Free PMC article.
Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity.
Bersani F, Picca F, Morena D, Righi L, Napoli F, Russo M, Oddo D, Rospo G, Negrino C, Castella B, Volante M, Listì A, Zambelli V, Benso F, Tabbò F, Bironzo P, Monteleone E, Poli V, Pietrantonio F, Di Nicolantonio F, Bardelli A, Ponzetto C, Novello S, Scagliotti GV, Taulli R. Bersani F, et al. Among authors: bardelli a. J Exp Clin Cancer Res. 2023 May 12;42(1):120. doi: 10.1186/s13046-023-02690-5. J Exp Clin Cancer Res. 2023. PMID: 37170152 Free PMC article.
Tolerance to colibactin correlates with homologous recombination proficiency and resistance to irinotecan in colorectal cancer cells.
Sogari A, Rovera E, Grasso G, Mariella E, Reilly NM, Lamba S, Mauri G, Durinikova E, Vitiello PP, Lorenzato A, Avolio M, Piumatti E, Bonoldi E, Aquilano MC, Arena S, Sartore-Bianchi A, Siena S, Trusolino L, Donalisio M, Russo M, Di Nicolantonio F, Lembo D, Bardelli A. Sogari A, et al. Among authors: bardelli a. Cell Rep Med. 2024 Feb 20;5(2):101376. doi: 10.1016/j.xcrm.2023.101376. Epub 2024 Jan 15. Cell Rep Med. 2024. PMID: 38228147 Free PMC article.
Preclinical efficacy of carfilzomib in BRAF-mutant colorectal cancer models.
Maione F, Oddo D, Galvagno F, Falcomatà C, Pandini M, Macagno M, Pessei V, Barault L, Gigliotti C, Mira A, Corti G, Lamba S, Riganti C, Castella B, Massaia M, Rad R, Saur D, Bardelli A, Di Nicolantonio F. Maione F, et al. Among authors: bardelli a. Mol Oncol. 2024 Jun;18(6):1552-1570. doi: 10.1002/1878-0261.13595. Epub 2024 Feb 13. Mol Oncol. 2024. PMID: 38348572 Free PMC article.
Post-surgery sequelae unrelated to disease progression and chemotherapy revealed in follow-up of patients with stage III colon cancer.
Mirandola A, Kudriavtsev A, Cofre Muñoz CI, Navarro RC, Macagno M, Daoud S, Sanchez C, Pastor B, Pisareva E, Marin MS, Ruiz JG, Piris A, Rodriguez AG, Gonzalez NS, Vivancos A, Quarà V, Mellano A, Borghi F, Corti G, Marchiò C, Sapino A, Bartolini A, Crisafulli G, Bardelli A, Di Maio M, Lossaint G, Frayssinoux F, Crapez E, Ychou M, Soler RS, Fenocchio E, Fernandez Calotti PX, Mazard T, Vivas CS, Elez E, Di Nicolantonio F, Thierry AR. Mirandola A, et al. Among authors: bardelli a. EBioMedicine. 2024 Oct;108:105352. doi: 10.1016/j.ebiom.2024.105352. Epub 2024 Sep 19. EBioMedicine. 2024. PMID: 39303668 Free PMC article.
Prediction of homologous recombination deficiency identifies colorectal tumors sensitive to PARP inhibition.
Corti G, Buzo K, Berrino E, Miotto M, Aquilano MC, Lentini M, Bellomo SE, Lorenzato A, Bartolini A, Mauri G, Lazzari L, Russo M, Di Nicolantonio F, Siena S, Marsoni S, Marchiò C, Bardelli A, Arena S. Corti G, et al. Among authors: bardelli a. NPJ Precis Oncol. 2024 Oct 14;8(1):231. doi: 10.1038/s41698-024-00706-7. NPJ Precis Oncol. 2024. PMID: 39402170 Free PMC article.
Case Report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer.
Mauri G, Patelli G, Gori V, Lauricella C, Mussolin B, Amatu A, Bencardino K, Tosi F, Bonazzina E, Bonoldi E, Bardelli A, Siena S, Sartore-Bianchi A. Mauri G, et al. Among authors: bardelli a. Front Oncol. 2022 Nov 7;12:1030232. doi: 10.3389/fonc.2022.1030232. eCollection 2022. Front Oncol. 2022. PMID: 36419886 Free PMC article.
368 results